Trial Profile
Phase I/II Study With the Combination of Dacomitinib and PD-0325901 in Metastatic KRAS Mutation Positive Non-small Cell Lung Cancer
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Mirdametinib (Primary) ; Dacomitinib; Docetaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms M13DAP
- 09 Mar 2020 Results published in the British Journal of Cancer
- 08 Nov 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 10 Nov 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2017.